Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Durvalumab + Mocetinostat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov). |
Mocetinostat | MGCD0103|MG-0103 | HDAC Inhibitor 38 | Mocetinostat (MGCD0103) selectively inhibits Class I histone-deacetelyases (HDACs), which may result in increased tumor cell death (PMID: 21317455, PMID: 20538840, PMID: 31534435). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02805660 | Phase Ib/II | Durvalumab + Mocetinostat | Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC | Terminated | USA | 0 |
NCT02993991 | Phase I | Durvalumab + Mocetinostat | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity | Withdrawn | CAN | 0 |